ArticleOncotarget2020

Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer.

Inês Gomes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.